Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 4/20 | 0.34 |
| ▸ | MMP2 | P08253 | 3/20 | 0.33 |
| ▸ | MMP8 | P22894 | 2/20 | 0.33 |
| ▸ | MMP13 | P45452 | 2/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2285746 | 1.00 | LMNA (0.61) | LMNAALDH1A1TP53KDM4ECYP3A4 | |
| SCHEMBL2048014 | 0.81 | MMP9 (0.42) | LMNATP53MMP9 | |
| SCHEMBL2048015 | 0.81 | MMP9 (0.42) | LMNATP53MMP9 | |
| Barbital SCHEMBL3859278 | 0.78 | LMNA (1.00) | LMNAALDH1A1TP53KDM4ECYP3A4 | |
| Barbital SCHEMBL43818 | 0.78 | LMNA (1.00) | LMNAALDH1A1TP53KDM4ECYP3A4 | |
| Etallobarbital SCHEMBL713588 | 0.78 | LMNA (0.64) | LMNAALDH1A1TP53KDM4ECYP3A4 | |
| Barbital SCHEMBL23533431 | 0.75 | LMNA (0.94) | LMNAALDH1A1TP53KDM4ECYP3A4 | |
| Barbital SCHEMBL11332231 | 0.75 | LMNA (0.94) | LMNAALDH1A1TP53KDM4ECYP3A4 | |
| Barbital SCHEMBL7592317 | 0.75 | LMNA (0.94) | LMNAALDH1A1TP53KDM4ECYP3A4 | |
| Barbital SCHEMBL21084955 | 0.75 | LMNA (0.94) | LMNAALDH1A1TP53KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 339 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600926-B2 | Treatment compositions with modified amino acid dimers for delivering a benefit agent | THE PROCTER & GAMBLE COMPANY (US) | 2026-04-14 | — | — | US | claimed |
| US-20260000592-A1 | TREATMENT COMPOSITIONS WITH ESTERAMINES OR SALTS THEREOF | PROCTER & GAMBLE (US) | 2026-01-01 | — | — | US | claimed |
| US-12509643-B2 | Pro-benefit-agent compounds with carbon/nitrogen bonds | THE PROCTER & GAMBLE COMPANY (US) | 2025-12-30 | — | — | US | claimed |
| EP-3784707-B1 | STABLE POLYUREA MICROCAPSULE COMPOSITIONS | INT FLAVORS & FRAGRANCES INC (US) | 2025-12-24 | — | — | EP | claimed |
| EP-4114914-B1 | FRAGRANCE PREMIX COMPOSITIONS AND RELATED CONSUMER PRODUCTS | PROCTER & GAMBLE (US) | 2025-06-25 | — | — | EP | claimed |
| US-20250129312-A1 | CONSUMER PRODUCT COMPOSITIONS WITH PERFUME ENCAPSULATES | PROCTER & GAMBLE (US) | 2025-04-24 | — | — | US | claimed |
| WO-2025051371-A1 | A FRAGRANCE PASTILLE | SYMRISE AG (DE) | 2025-03-13 | — | — | WO | claimed |
| WO-2025045354-A1 | A FRAGRANCE TABLET | SYMRISE AG (DE) | 2025-03-06 | — | — | WO | claimed |
| WO-2025045353-A1 | A FRAGRANCE POD | SYMRISE AG (DE) | 2025-03-06 | — | — | WO | claimed |
| US-12209232-B2 | Consumer product compositions with perfume encapsulates | THE PROCTER & GAMBLE COMPANY (US) | 2025-01-28 | — | — | US | claimed |
| US-6982288-B2 | Dental cements, filling materials, adhesives | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-01-03 | — | — | US | claimed |
| JP-2005524682-A | — | — | 2005-08-18 | — | — | JP | claimed |
| EP-1496837-A1 | MEDICAL COMPOSITIONS CONTAINING AN IONIC SALT | 3M Innovative Properties Company (US) | 2005-01-19 | — | — | EP | claimed |
| EP-1458831-A2 | COMPOSITION CONTAINING A POLYMERIZABLE REDUCING AGENT, KIT, AND METHOD | 3M Innovative Properties Company (US) | 2004-09-22 | — | — | EP | claimed |
| WO-2003086328-A1 | MEDICAL COMPOSITIONS CONTAINING AN IONIC SALT | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-10-23 | — | — | WO | claimed |
| US-20030195273-A1 | Medical compositions containing an ionic salt, kits, and methods | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-16 | — | — | US | claimed |
| US-20030166740-A1 | Composition containing a polymerizable reducing agent, kit, and method | 3M INNOVATIVE PROPERTIES COMPANY | 2003-09-04 | — | — | US | claimed |
| WO-2003057792-A2 | COMPOSITION CONTAINING A POLYMERIZABLE REDUCING AGENT, KIT, AND METHOD | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-07-17 | — | — | WO | claimed |
| EP-1067942-A1 | HIGH-ENERGY CYCLODEXTRIN COMPLEXES | Cyclops, EHF. (IS) | 2001-01-17 | — | — | EP | claimed |
| WO-1999042111-A1 | HIGH-ENERGY CYCLODEXTRIN COMPLEXES | CYCLOPS, EHF. (IS) | 1999-08-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509643-B2 | Pro-benefit-agent compounds with carbon/nitrogen bonds | HGFAC, PROKR1, FABP2 | LMNA 5/4885ALDH1A1 544/4885TP53 1914/4885 |
| US-20260000592-A1 | TREATMENT COMPOSITIONS WITH ESTERAMINES OR SALTS THEREOF | ARGLU1, DAO, PNISR | LMNA 3119/4885ALDH1A1 4253/4885TP53 1004/4885 |
| US-12600926-B2 | Treatment compositions with modified amino acid dimers for delivering a benefit agent | F2, C9, S100A8 | LMNA 185/4885ALDH1A1 2233/4885TP53 1043/4885 |
| US-20030195273-A1 | Medical compositions containing an ionic salt, kits, and methods | NOX4, SCN4A, IL4 | LMNA 2934/4885ALDH1A1 1883/4885TP53 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.